PMID- 18081375
OWN - NLM
STAT- MEDLINE
DCOM- 20080228
LR  - 20211020
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 68
IP  - 1
DP  - 2008
TI  - Parnaparin : a review of its use in the management of venous thromboembolism, 
      chronic venous disease and other vascular disorders.
PG  - 105-22
AB  - Parnaparin (Fluxum) is a low molecular weight heparin (LMWH) that is effective 
      and generally well tolerated in the prevention of venous thrombosis, and in the 
      treatment of chronic venous disease and venous and arterial thrombosis. Overall, 
      the efficacy of parnaparin is at least as good as that of unfractionated heparin 
      (UFH), but recent data indicate that parnaparin is more effective in preventing a 
      triple composite endpoint of death, acute myocardial infarction (MI) and 
      myocardial revascularisation in patients with unstable angina or acute ST-segment 
      elevation myocardial infarction (STEMI). As with other LMWHs, parnaparin has a 
      more convenient, once-daily, subcutaneous administration regimen and better local 
      tolerability than UFH. Very little evidence comparing LMWHs is available but, 
      because of similarities between these agents, very large studies would be needed 
      to show significant differences. Meanwhile, data indicate that parnaparin is a 
      useful option in the range of available LMWHs.
FAU - McKeage, Kate
AU  - McKeage K
AD  - Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.c.nz
FAU - Keating, Gillian M
AU  - Keating GM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - M316WT19D8 (parnaparin)
SB  - IM
MH  - Anticoagulants/administration & dosage/adverse 
      effects/pharmacokinetics/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Chronic Disease
MH  - Drug Administration Schedule
MH  - Fibrinolytic Agents/administration & dosage/adverse 
      effects/pharmacokinetics/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/administration & dosage/adverse 
      effects/pharmacokinetics/*therapeutic use
MH  - Humans
MH  - Treatment Outcome
MH  - Venous Thromboembolism/*drug therapy
RF  - 62
EDAT- 2007/12/18 09:00
MHDA- 2008/02/29 09:00
CRDT- 2007/12/18 09:00
PHST- 2007/12/18 09:00 [pubmed]
PHST- 2008/02/29 09:00 [medline]
PHST- 2007/12/18 09:00 [entrez]
AID - 6817 [pii]
AID - 10.2165/00003495-200868010-00007 [doi]
PST - ppublish
SO  - Drugs. 2008;68(1):105-22. doi: 10.2165/00003495-200868010-00007.